Quest Diagnostics Study Finds 69.5% of Klebsiella Pneumoniae Resistant to Top Oral Antibiotics
DGX•Quest Diagnostics researchers screened 2,000 samples across 42 states and found that 100% of Klebsiella pneumoniae isolates were multidrug resistant, with 69.5% non-susceptible to the three most common oral antibiotics. The CTX-M-15 gene has spread across 267 sequence types, signaling urgent demand for new oral treatments.
1. Study Scope and Findings
Quest Diagnostics researchers provided over 2,000 deidentified Klebsiella pneumoniae isolates from 42 states for sequencing, revealing that every sample was multidrug resistant. Of these isolates, 69.5% were non-susceptible to fluoroquinolones, Bactrim and nitrofurantoin, highlighting widespread community transmission beyond hospital settings.
2. Resistance Mechanisms Identified
Analysis identified 267 distinct multidrug-resistant sequence types driven by the CTX-M-15 gene, which confers resistance and enhances survival through plasmid transfer. This gene also imparts stress and metal tolerance, potentially boosting the pathogen’s ability to persist outside human hosts.
3. Implications for Diagnostics and Treatments
The lack of effective oral antibiotics may shift treatment toward injectable options and drives demand for novel drug development and diagnostic assays. Quest Diagnostics’ nationwide lab network positions the company to expand testing services for emerging resistant strains.
4. Next Steps and Research Directions
Ongoing surveillance of community-associated resistance patterns will be crucial to track new high-risk clones. The genetic data establishes a baseline for vaccine and therapeutic development, underscoring the need for partnerships between diagnostic providers and research institutions.
